Search clinical trials for: NVP-2002

Total 3359 results

NVP Healthcare

Completed

Pharmacokinetic Characteristics and Safety After Administration of NVP-2002

Healthy

Korea, Republic of
NVP Healthcare

Completed

Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects

Healthy Subjects

Korea, Republic of
Vyluma, Inc.
Syneos Health

Active, not recruiting

CHAMP: Study of NVK-002 in Children With Myopia

Myopia

United States, Hungary, Ireland, Netherlands, Spain, United Kingdom
GlaxoSmithKline

Completed

Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03

Influenza

Germany
Erasmus Medical Center
University Medical Center Groningen; Leiden University Medical Center

Recruiting

NRP vs DHOPE vs COR-NMP in ECD-DCD Donation

Complication of Surgical Procedure | Liver Transplant | Organ Perfusion

Netherlands
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
NVP Healthcare

Recruiting

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases

Korea, Republic of
NVP Healthcare

Completed

Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 (Navipharm)

Healthy

Korea, Republic of
NVP Healthcare

Completed

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Healthy

Korea, Republic of
NVP Healthcare

Withdrawn

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2

Healthy
NVP Healthcare

Completed

Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain

Acute Low Back Pain

Korea, Republic of
NVP Healthcare

Completed

Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain

Acute Low Back Pain

Korea, Republic of
NVP Healthcare

Completed

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

Healthy Volunteers

Korea, Republic of
NVP Healthcare

Completed

Compare the Pharmacokinetics of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2 (NVP-1805)

Healthy

Korea, Republic of
NVP Healthcare

Completed

NVP-1805 Compared to Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Adult Volunteers (BE)

Healthy Volunteers

Korea, Republic of
GlaxoSmithKline

Completed

Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years

Influenza

Germany
Johns Hopkins University

Recruiting

Microvascular Plug (MVP) for the Treatment of Pulmonary ArterioVenous Malformations (PAVMs)

Pulmonary Arteriovenous Malformation

United States
ARYx Therapeutics

Completed

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

Atrial Fibrillation

United States, Canada
NVP Healthcare

Completed

A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402

Healthy

Korea, Republic of
NVP Healthcare

Completed

Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects

Healthy Subjects

Korea, Republic of
Novartis Vaccines

Completed

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza

Italy
PATH
VA Puget Sound Health Care System; Seattle Institute for Biomedical and Clinical...

Completed

Intradermal Influenza Vaccine Study in Elders

Influenza
NVP Healthcare

Completed

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Healthy Volunteers

Korea, Republic of
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age (SLVP016)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Influenza

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites

Parkinson's Disease

Switzerland
Seattle Children's Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

Inactivated Influenza Vaccine

United States
GlaxoSmithKline

Completed

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above

Influenza

Germany
Boehringer Ingelheim

Completed

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

HIV Infections
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Surakameth Mahasirimongkol
Chulalongkorn University; National Institutes of Health (NIH); Mahidol University and other collaborators

Completed

Genotype Based Personalized Prescription of Nevirapine (GENPART)

HIV Infections | HIV | AIDS | Nevirapine Induced Rash | Nevirapine Induced Hepatitis | Adverse Side Effects

Thailand
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
NVP Healthcare

Completed

A Study to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 (NVP-1203)

Healthy

Korea, Republic of
NVP Healthcare

Completed

The Food Effect on the Pharmacokinetics of NVP-1402

Healthy

Korea, Republic of
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

Influenza

Italy
University Psychiatric Clinics Basel
University of Basel

Not yet recruiting

ID-ClimAct. Influence of Social Motives of Clients and Staff on the Social Climate of Secure Settings (ID-ClimAct)

Interpersonal Relations | Social Dominance | Social Environment | Correctional Institutions | Rehabilitation of Criminals

Switzerland
Anne Chang
Novartis

Completed

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Basal Cell Carcinoma

United States
Shahid Beheshti University of Medical Sciences

Completed

Antibody Response to Influenza Vaccine in Patients With Sarcoidosis (IVS)

Pulmonary Sarcoidosis

Iran, Islamic Republic of
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

Influenza

Italy
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects

Influenza

Germany
GlaxoSmithKline

Completed

Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over

Influenza

Norway, Estonia, Denmark
Columbia University

Completed

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Uveal Melanoma

United States
Rio de Janeiro State University

Completed

Obstructive Sleep Apnea and Endothelial Function in Patients With Resistant Hypertension

Obstructive Sleep Apnea | Secondary Hypertension

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Follow-up in Pediatric Intensive Care Unit (APRELAREA)

Intensive Care Psychosis

France
Mayo Clinic
Qatar National Research Fund

Completed

Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome

Acute Coronary Syndrome

United States
Queen's University

Terminated

Cardiac Resynchronization Therapy, Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure (CHF)

Congestive Heart Failure

Canada

3

Subscribe